Praetego is biopharma company developing first-in-class Advanced Glycation End-product (AGE) inhibitors able to deter AGE formation at the initiation of pathology. Through this novel and proprietary small molecule technology, Praetego’s candidates are designed to slow or prevent diseases driven by oxidative stress. This includes the highly burdensome diseases of Neurodegeneration / Alzheimer's disease, Diabetic Neuropathy and Diabetic Retinopathy. Praetego’s AGE inhibitor platform technology applies to the chronic conditions of aging.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
PTG-630
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
